Franco Ionna

Franco Ionna

Auto-generated profile, based on publicly available information

Franco Ionna

Complex Structure of Maxillofacial Surgery and ORL, National Cancer Institute – IRCCS – Fondazione G. Pascale Naples , Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2015 in Oncology
Verified
Journal Article
Closed access
FPFrancesca Pezzuto
Francesca Pezzuto
Luigi BuonaguroLuigi Buonaguro
Luigi Buonaguro
FCFrancesco Caponigro
Francesco Caponigro
FIFranco Ionna
Franco Ionna
NSNoemy Starita
Noemy Starita
Maria Lina TorneselloMaria Lina Tornesello
Maria Lina Tornesello
Tobacco use and alcohol consumption are the main risk factors associated with head and neck squamous cell carcinoma (SCC) development due to their cytotoxic and mutagenic effects on the exposed epithelia of the upper aerodigestive tract. Epstein-Barr virus (EBV) and high-risk human papillomaviruses (HPVs), both encoding viral oncoproteins able to interfere with cell cycle control, have been recognized as the etiological agents of nasopharynx carcinoma and a fraction of oropharyngeal carcinoma, respectively. Head and neck SCC is a deadly disease and despite innovative treatments represents a major challenge for patients. Recently, a number of genomic studies have highlighted the molecular heterogeneity of head and neck SCC based on methylation profiles, microRNA expression, mutated genes and new druggable pathways which may represent new targets for cancer-tailored therapies. To date, cetuximab is the only FDA-approved anti-epidermal growth factor receptor therapy for the treatment of head and neck SCC. In addition, a number of monoclonal antibodies targeting AKT, mTOR and PI3K pathways are under evaluation. Several therapeutic vaccines against HPV16 and EBV proteins are also under study. The purpose of this article is to review the epidemiology, pathogenesis and molecular features of head and neck SCC, with an emphasis on new therapies.

1 June 2010 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
FCFrancesco Caponigro
Francesco Caponigro
Francesco LongoFrancesco Longo
Francesco Longo
FIFranco Ionna
Franco Ionna
FPFrancesco Perri
Francesco Perri
Early-stage nasopharyngeal carcinoma (T1–2a;N0;M0) represents a small proportion of nasopharyngeal tumors. Radiotherapy alone is the current treatment approach for this tumor and the emerging role of new radiotherapy techniques will hopefully further improve the treatment outcome for these patients. The vast majority of patients with nasopharyngeal carcinoma is diagnosed with locally advanced disease. Concomitant chemoradiotherapy is now acknowledged as being a standard treatment option, even though it induces a considerable incidence of acute mucosal and hematologic toxicity. The issue of adding adjuvant chemotherapy is somewhat more controversial. Similarly, the role of neoadjuvant chemotherapy before concomitant chemoradiotherapy is a matter of interest. In patients with recurrent/metastatic nasopharyngeal carcinoma the prognosis is generally grim, as platinum-based chemotherapy results in a 50–70% response rate and in a median survival time of 11 months. Several trials have been performed on this subset of patients with both cytotoxic and biologic agents, but the results have not been particularly encouraging thus far. Epstein–Barr virus is associated with the vast majority of nasopharyngeal carcinoma. Concentrations of plasma Epstein–Barr virus DNA have been associated with treatment outcome in the clinic. Immunotherapy is generally well tolerated and can sometimes elicit significant immune response, which possibly induces clinical benefit in some patients.

8 October 2004 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
RBRoberto Bei
Roberto Bei
Alfredo BudillonAlfredo Budillon
Alfredo Budillon
LMLaura Masuelli
Laura Masuelli
VCVittore Cereda
Vittore Cereda
DVDomenico Vitolo
Domenico Vitolo
RMRaffaella Muraro
Raffaella Muraro

31 March 2014 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
GPG. Pannone
G. Pannone
Angela santoroAngela santoro
Angela santoro
Antonia FeolaAntonia Feola
Antonia Feola
PBP. Bufo
P. Bufo
PPP. Papagerakis
P. Papagerakis
MDMarina Di Domenico
Marina Di Domenico
Background: The prognosis of the oral squamous cell carcinoma (OSCC) patients remains very poor, mainly due to their high propensity to invade and metastasize. E-cadherin reduced expression occurs in the primary step of oral tumour progression and gene methylation is a mode by which the expression of this protein is regulated in cancers. In this perspective, we investigated E-cadherin gene (CDH1) promoter methylation status in OSCC and its correlation with Ecadherin protein expression, clinicopathological characteristics and patient outcome. Methods: Histologically proven OSCC and paired normal mucosa were analyzed for CDH1 promoter methylation status and E-cadherin protein expression by methylation-specific polymerase chain reaction and immunohistochemistry. Colocalization of E-cadherin with epidermal growth factor (EGF) receptor (EGFR) was evidenced by confocal microscopy and by immunoprecipitation analyses. Results: This study indicated E-cadherin protein down-regulation in OSCC associated with protein delocalization from membrane to cytoplasm. Low E-cadherin expression correlated to aggressive, poorly differentiated, high grade carcinomas and low patient survival. Moreover, protein down-regulation appeared to be due to E-cadherin mRNA downregulation and CDH1 promoter hypermethylation. In an in vitro model of OSCC the treatment with EGF caused internalization and co-localization of E-cadherin with EGFR and the addition of demethylating agents increased E-cadherin expression. Conclusion: Low E–Cadherin expression is a negative prognostic factor of OSCC and is likely due to the hypermethylation of CDH1 promoter. The delocalization of E-cadherin from membrane to cytoplasm could be also due to the increased expression of EGFR in OSCC and the consequent increase of E-cadherin co-internalization with EGFR.

29 December 2011 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LMLaura Masuelli
Laura Masuelli
Alfredo BudillonAlfredo Budillon
Alfredo Budillon
LMLaura Marzocchella
Laura Marzocchella
MMMarie‐Agnes Mrozek
Marie‐Agnes Mrozek
DVDomenico Vitolo
Domenico Vitolo
Roberto BeiRoberto Bei
Roberto Bei

10 June 2014 in International Journal of Dentistry
Verified
Journal Article
Open access
PDF file
Francesco LongoFrancesco Longo
Francesco Longo
Agostino GuidaAgostino Guida
Agostino Guida
CAC. Aversa
C. Aversa
EPE. Pavone
E. Pavone
GCG. Di Costanzo
G. Di Costanzo
FIF. Ionna
F. Ionna
Bisphosphonates (BPs) are a class of synthetic drugs commonly used to treat bone metastasis and various bone diseases that cause osseous fragility (such as osteoporosis). Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a common complication in patients who received BPs, especially intravenously. Recently, osteonecrosis of the jaw (ONJ) caused by chemotherapeutic not belonging to BPs drug class has been reported. For this reason, it has been proposed recently to rename BRONJ in antiresorptive agents related osteonecrosis of the jaw (ARONJ), to include a wider spectrum of drugs that may cause osteonecrosis of the jaw. The most debated topic about ARONJ/BRONJ is therapy. The most adequate procedure is far from being standardized and prevention seems to play a pivotal role. In our study, we considered 72 patients with BRONJ with nonsurgical therapy, surgical therapy, and surgical therapy with platelet rich plasma (PRP) gel to evaluate its therapeutic effect in promoting ONJ wounds healing. Good results showed by PRP in improving wound healing give away to case-control randomized studies that could give definitive evidence of its effectiveness.